|Drug Name||GPCR-targeted Project 001|
A monoclonal antibody that acts as a thyroid stimulating hormone receptor (TSHR) antagonist is in early clinical development for the treatment of patients with Graves’ disease or thyroid cancer. Grave’s disease is an autoimmune disease that leads to a generalized overactivity of the entire thyroid gland (hyperthyroidism).
|Target||Thyroid stimulating hormone receptor (TSHR)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||TSHR antagonists|
We look forward to hearing from you.